Angiogenesis, Exudation, and Degeneration 2017

February 11, 2017
Mandarin Oriental, Miami, FL

Program Directors: Philip J. Rosenfeld, MD, PhD and Harry W. Flynn, Jr., MD
Course Associate Director: Carmen A. Puliafito, MD, MBA

PROGRAM
Subject to Change

Saturday, February 11, 2017

7:00 am Registration and Continental Breakfast

7:55 Welcome and Overview
Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Carmen A. Puliafito, MD, MBA

Session I: Age-Related Macular Degeneration
Moderator: Philip J. Rosenfeld, MD, PhD

8:00 Genetics and Nutrition in AMD
Emily Y. Chew, MD

8:10 The Oil Spill Strategies for AMD: Update and Model System
Christine A. Curcio, PhD, FARVO

8:20 Cuticular Drusen: New Clinical Pathological Observations
Lawrence A. Yannuzzi, MD

8:30 Update from CAM: A Proposed Classification System for Atrophy
SriniVas R. Sadda, MD

8:40 Using AMD Geographic Atrophy Area as a Clinical Trial Primary Outcome Variable
Frederick L. Ferris, III, MD

8:50 Genetic Variants and AMD Progression
Carel B. Hoyng, MD

9:00 Mechanisms of Low Luminance Vision Loss in AMD
Karl G. Csaky, MD, PhD
Computational Approaches to Modeling Compromise in the Choroidal Circulation
Philip Luthert, MB BS

Choriocapillaris Death is an Early Event in Neovascular AMD
Gerard A. Lutty, PhD

Session II: OCT Angiographic Imaging
Moderator: Carmen A. Puliafito, MD, MBA

The Role of the Choriocapillaris in Non-Exudative AMD:
An OCT Angiography Based Evaluation
Nadia Waheed, MD

SS-OCT Angiographic Imaging of the Choriocapillaris in AMD
Fang Zheng, MD

VISTA – Making OCTA Quantifiable
Jay S. Duker, MD

OCT Angiographic Prevalence and Natural History of Non-Exudative Neovascular AMD
Joao Rafael De Oliveira Dias, MD

SD-OCTA vs. SS-OCTA Imaging of CNV in AMD
Philip J. Rosenfeld, MD, PhD

Biomarkers of Neovascular Activity Using OCT Angiography
David Sarraf, MD

Session III: Emerging Therapies
Moderator: Philip J. Rosenfeld, MD, PhD

Top Innovations in Retina – A VC’s Perspective
Emmett T. Cunningham, Jr., MD, PhD, MPH

Lipids as Therapeutic Targets in Dry AMD
Rajendra S. Apte, MD, PhD

Macrophage Polarization as Therapeutic Target in Dry AMD
Shelley Boyd, DABO, MD, FRCS(C), BSc

Update of Elamipretide (MTP-131) for Dry AMD
Scott W. Cousins, MD

Complement C3 Inhibition in AMD
Cedric G. Francois, MD, PhD
11:20 Development of a MAC Inhibitor for Dry AMD Using a Gene Therapy Approach
Elias Reichel, MD

11:30 Intravitreal Approaches to Retinal Gene Therapy: Results from Second Generation Vectors and Molecules
David M. Brown, MD, FACS

11:40 Technical Aspects of Gene Delivery in AMD by Sub Retinal Surgical Approaches: Imaging Results and the Efficacy Impact of Location of Injection and Choice of Agent
Szilárd Kiss, MD

11:50 A Sustained Release Liposomal Delivery System
Peter K. Kaiser, MD

Session IV: Neovascular Age-Related Macular Degeneration
Moderator: Zohar Yehoshua, MD, MHA

12:00 Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated in the VIEW Trials
K. Bailey Freund, MD

12:10 Long Term Outcomes in Patients Treated for Neovascular AMD
Daniel F. Martin, MD

12:20 Progression Rate of RPE Loss in Patients with Neovascular AMD Treated with Different VEGF Inhibitors
Stephan Michels, MD MBA

12:30 Long-Term Treatment with Intravitreal Aflibercept Injection in Patients Completing the VIEW and VIEW 1 Extension Studies: Two Year Results of the RANGE Study
W. Lloyd Clark, MD

12:40 Functional and Anatomic Outcomes 1 Year Following Conversion to Conbercept in Chinese Patients with Neovascular Age-Related Macular Degeneration:
A Case Series study
Xiaodong Sun, MD

12:50 Brolucizumab vs. Aflibercept Treatment for Neovascular AMD
Lawrence J. Singerman, MD, FACS, FICS

1:00 Risk Factors for Fibrosis in the Anti-VEGF Era
Usha Chakravarthy, MD

1:10 Lunch
Session V: Neovascular AMD: Combination Therapies  
Moderator: Carmen A. Puliafito, MD, MBA

2:00 Anti-PDGF Therapy for Neovascular AMD  
Pravin U. Dugel, MD

2:10 Morphology-Visual Acuity Correlations after anti-VEGF/anti-PDGF Therapy for Neovascular AMD  
Glenn J. Jaffe, MD

2:20 Combination Therapy with Aflibercept for the Treatment of Neovascular AMD  
Jeffrey S. Heier, MD

2:30 Icon-1 in the Treatment of Neovascular AMD: Phase 2a Study Results  
Carl D. Regillo, MD, FACS

2:40 Topical Squalamine for Neovascular AMD: An Update  
Jason S. Slakter, MD

Session VI: Stem Cells and Retinal Degenerations  
Moderator: Wen-Hsiang Lee, MD, PhD

Thomas A. Albini, MD

3:00 Long-Term Outcomes of hESC-Derived RPE Cell Transplantation in Atrophic AMD and Stargardt Disease  
Ninel Z. Gregori, MD

3:10 Stem Cell Derived RPE Transplantation - An Update of the London Project  
Lyndon Da Cruz, MD

3:20 Embryonic Stem cell-Derived RPE: The California Project, A Phase 1/2a Clinical Trial  
David R. Hinton, PhD

3:30 Subretinal Transplantation of RPE Cells Derived from Human Embryonic Stem Cells in Patients with Advanced Dry AMD: Observations from the Hadassah Phase I/IIa Clinical Trial  
Eyal Banin, MD PhD

3:40 Autologous iPSC-RPE Cell Therapy for AMD  
Kapil Bharti, PhD
3:50 Toward More Precise Sub Retinal Therapeutic Delivery: New Techniques and Instrumentation  
   Allen C. Ho, MD

4:00 Clinical Translation of Retinal Progenitors Cells for RP: The jCyte Experience  
   Henry J. Klassen, MD PhD

4:10 Update on Clinical Trials for Retinal Degenerations  
   Byron L. Lam, MD

Session VII: Diabetic Retinopathy  
Moderator: Harry W. Flynn, Jr., MD

4:20 DRCR.net Update  
   Harry W. Flynn, Jr., MD

4:30 Slurry Kenalog: A Lower Cost, Quick and Easy Alternative for Long-Term Intraocular Steroid Delivery  
   Susan M. Malinowski, MD, FACS

4:40 Update on Aflibercept Pharmacokinetics and Treatment of Diabetic Macular Edema  
   Diana V. Do, MD

4:50 Ziv-Aflibercept in Diabetic Macular Edema  
   Michel E. Farah, MD

5:00 ENDURANCE Extension Study Following the VISTA DME Study  
   Charles C. Wykoff, MD PhD

5:10 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study  
   Justis P. Ehlers, MD

5:20 Anti-Integrin Treatment for Diabetic Edema  
   David S. Boyer, MD

5:30 Impact of Cataract Surgery on Visual Acuity and OCT in DME Patients Undergoing Anti-VEGF Therapy  
   Andrew A. Moshfeghi, MD, MBA
Session VIII: Uveitis and Retinal Vascular Diseases
Moderator: Jaclyn L. Kovach, MD

5:40  Intravitreal Sirolimus for Non-Infectious Uveitis: Primary Outcomes of the Phase3 SAKURA 2 Study
     Quan D. Nguyen, MD, MSc

5:50  Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Trial
     Peter A. Campochiaro, MD

6:00  MacTel Project Update
     Martin Friedlander, MD, PhD

6:10  Near-Term Safety of Bevacizumab in Treatment of Retinopathy of Prematurity
     Darius M. Moshfeghi, MD

6:20  Advances in Mobile Device Enabled Retinal Fundus Photography for Clinical Research and Public Health Screening
     Mark S. Blumenkranz, MD

6:30  Adjourn/Cocktail Reception